DK1845966T3 - Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme - Google Patents

Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme

Info

Publication number
DK1845966T3
DK1845966T3 DK06700207.1T DK06700207T DK1845966T3 DK 1845966 T3 DK1845966 T3 DK 1845966T3 DK 06700207 T DK06700207 T DK 06700207T DK 1845966 T3 DK1845966 T3 DK 1845966T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
pharmaceutical composition
glutamine
alpha
Prior art date
Application number
DK06700207.1T
Other languages
English (en)
Inventor
Martyna Kandefer-Szerszen
Stephan Pyerzynowski
Wojciech Rzeski
Original Assignee
Sgp & Sons Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab
Application granted granted Critical
Publication of DK1845966T3 publication Critical patent/DK1845966T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK06700207.1T 2005-01-11 2006-01-10 Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme DK1845966T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL372183A PL372183A1 (pl) 2005-01-11 2005-01-11 Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
PCT/PL2006/000003 WO2006075924A1 (en) 2005-01-11 2006-01-10 Antineoplastic preparation and the use of antineoplastic preparation

Publications (1)

Publication Number Publication Date
DK1845966T3 true DK1845966T3 (da) 2010-11-08

Family

ID=36168380

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06700207.1T DK1845966T3 (da) 2005-01-11 2006-01-10 Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme

Country Status (12)

Country Link
US (1) US7759396B2 (da)
EP (1) EP1845966B1 (da)
JP (2) JP2008526838A (da)
CN (1) CN101111241B (da)
AT (1) ATE474570T1 (da)
AU (1) AU2006205279B2 (da)
CA (1) CA2593780C (da)
DE (1) DE602006015608D1 (da)
DK (1) DK1845966T3 (da)
ES (1) ES2349233T3 (da)
PL (2) PL372183A1 (da)
WO (1) WO2006075924A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
WO2015123229A1 (en) * 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms
WO2025263592A1 (ja) * 2024-06-19 2025-12-26 Agc株式会社 グルタミン代謝阻害剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
FR2775901B1 (fr) * 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
CN1802152A (zh) 2002-08-01 2006-07-12 艾斯根公司 用谷氨酰胺改善癌症的治疗
AT412447B (de) * 2002-11-27 2005-03-25 C Y L Handelsges M B H Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
ES2275218T3 (es) * 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US20050124684A1 (en) * 2003-08-29 2005-06-09 Ying Du 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
AU2005316295B2 (en) * 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease

Also Published As

Publication number Publication date
CN101111241A (zh) 2008-01-23
JP2008526838A (ja) 2008-07-24
US20080058422A1 (en) 2008-03-06
WO2006075924A1 (en) 2006-07-20
ATE474570T1 (de) 2010-08-15
PL372183A1 (pl) 2006-07-24
CN101111241B (zh) 2010-12-01
PL1845966T3 (pl) 2011-02-28
AU2006205279B2 (en) 2011-05-26
AU2006205279A1 (en) 2006-07-20
EP1845966A1 (en) 2007-10-24
DE602006015608D1 (de) 2010-09-02
CA2593780C (en) 2013-11-26
EP1845966B1 (en) 2010-07-21
ES2349233T3 (es) 2010-12-29
CA2593780A1 (en) 2006-07-20
US7759396B2 (en) 2010-07-20
JP2013035864A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
TNSN07452A1 (en) Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
EP2584043A3 (en) Anti-glypican 3 antibody having improved kinetics in plasma
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
SE1651735A1 (en) Substances for treatment of fatty liver-related conditions
TW200634051A (en) Processes for preparing a polypeptide
CO6290629A2 (es) Composiciones de limpieza de amino ácido básico y métodos
ZA200707508B (en) 2-[isoquinolin-3-carbonyl) amino] -propionic acid derivatives as inhibitors of factors XI and IX for the treatment of thrombosis
BRPI0606301A2 (pt) processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
ZA201005615B (en) Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
DK1583430T3 (da) Fremgangsmåde til fremstilling af en sammensætning til supplement til dyr med oplösninger af essentielle aminosyremetalkomplekser
WO2008099874A1 (ja) ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法
DK1290011T3 (da) Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
WO2006062424A3 (en) Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
TNSN07228A1 (en) Manufacture process of organic compounds
ATE540679T1 (de) Verfahren zur verringerung der gastrointestinalen toxizität durch verabreichung von tegafur
PL1845966T3 (pl) Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych
TNSN07229A1 (en) Manufacture process of n-substituted salicylamides
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
ATE536342T1 (de) Neue carbamoylglycinderivate
EP1774966A4 (en) MEANS TO INHIBIT THE USE AND PROGRESS OF LIVER CANCER IN PATIENTS WITH HEPATITIS C-VIRUS POSITIVE LIVER CIRR